A common challenge for investors is finding companies with both good business momentum and favorable price action. One method to address this is by combining fundamental and technical analysis, seeking stocks that show good growth, profitability, and financial health while also showing technical breakout patterns. This approach aims to find companies where improving business fundamentals may be coming together with positive market sentiment, possibly signaling a continued upward move. One stock currently meeting these combined criteria is Neurocrine Biosciences Inc (NASDAQ:NBIX).
A Focus on Neuroscience Growth
Neurocrine Biosciences operates as a biopharmaceutical company focused on discovering and developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Its commercial portfolio includes approved therapies for conditions such as tardive dyskinesia and chorea associated with Huntington’s disease. The company’s focused approach in the neuroscience sector represents a large and growing market, matching the qualitative condition for growth investing that highlights a big and increasing target market with significant unmet medical needs.
Fundamental Strength: Profitability and Growth
The fundamental case for Neurocrine is strong, as detailed in its fundamental analysis report. The company receives high scores in key areas important for a growth stock.
-
High Profitability: Neurocrine scores an 8 out of 10 on the ChartMill Profitability Rating. Key metrics are notable:
- A Return on Invested Capital (ROIC) of 11.10%, doing better than nearly 95% of its biotechnology industry peers.
- A good Operating Margin of 20.64% and a Profit Margin of 15.95%, both ranking with the best in the sector.
- Consistent profitability with positive earnings and operating cash flow over the past five years.
-
Good and Continued Growth: The company’s Growth Rating is also a solid 8. It has delivered notable historical expansion and is expected to continue on this path.
- Revenue has grown at an average yearly rate of 24.48% over recent years.
- Earnings Per Share (EPS) has increased at an average rate of 58.39% yearly.
- Looking forward, analysts project EPS growth of about 35% on average for the coming years.
-
Good Financial Health: With a Health Rating of 7, Neurocrine keeps a firm balance sheet. A major positive is its lack of debt, giving financial flexibility and lowering risk. This good health foundation is a key screen criterion, as it indicates the company has the stability to fund its growth plans and handle market changes.
Technical Setup: Aligning with Positive Trends
The technical picture supports the good fundamentals. Neurocrine’s technical analysis report gives a high rating of 9, supported by several positive factors.
- Positive Trend Alignment: Both the short-term and long-term trends for NBIX are positive, a key sign of continued buyer interest. The stock is trading above its key moving averages (20, 50, 100, and 200-day SMAs), which are all pointing upward.
- Good Relative Performance: The stock is doing well on an absolute and relative basis. It is trading near its 52-week high and has done better than about 77% of all stocks in the market over the past year.
- Consolidation and Breakout Possibility: The stock has been trading in a set range over the past month. The technical setup shows it is currently testing a resistance zone between $152.38 and $154.81. A clear move above this zone could signal a new breakout phase, matching the screen’s aim of finding good technical patterns in fundamentally sound companies.
Valuation Context
While the stock’s standalone Price-to-Earnings (P/E) ratio seems high, its valuation looks more appealing within its high-growth industry context. Neurocrine is less expensive than over 91% of its biotechnology peers based on both its current and forward P/E ratios. Also, its low PEG ratio, which includes earnings growth, suggests the market may not be fully accounting for its good future growth prospects. This mix of good growth at a fair relative valuation is a feature of many successful growth stock investments.
Conclusion
Neurocrine Biosciences presents a case where fundamental strength and technical momentum appear to be coming together. The company shows the features of a good growth stock, high profitability, increasing revenue and earnings, and a clean balance sheet, all within the large neuroscience market. Technically, the stock is in a confirmed uptrend and is positioned near a possible breakout level. This combination of a healthy, growing business and positive price action is exactly what the combined screening method seeks to find.
For investors interested in exploring other stocks that meet similar criteria of good growth, solid fundamentals, and promising technical setups, you can review the full screen results here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy or sell any security, or an endorsement of any investment strategy. All investments involve risk, including the potential loss of principal. Investors should conduct their own research and consider their individual financial circumstances before making any investment decisions.
